Introduction
Multifunctional cytokine interleukin-12 (IL-12) is a 70 kDa (p70) heterodimeric protein in which the 40 kDa (p40) and 35 kDa (p35) subunits are connected by one disulfide bond.
1,2 IL-12 is mainly secreted by antigenpresenting cells including dendritic cells (DCs) and macrophages and is known for its antitumor properties, effected through the induction of specific cellular immune responses, such as the enhancement of proliferative and cytotoxic activities of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), 3, 4 the production of interferon-g (IFN-g) from activated cells, [4] [5] [6] and the promotion of helper T type 1 (Th1) cell differentiation from Th0 cells. 4, 7, 8 IFN-g is involved in IL-12-mediated tumor regression, 9 and IL-12 also exhibits an antiangiogenic effect that can account for some antitumor activity. 10 Although recombinant IL-12 administration at high doses is effective for cancer treatment, major drawbacks of this therapy are the serious adverse effects associated with high systemic peak IL-12 concentrations. 11, 12 Moreover, even in gene therapy aiming for persistent local IL-12 expression by using intratumoral injection of a vector carrying the IL-12 gene, careful evaluation of the vector dosage is required to restrict IL-12 leakage from the tumor tissue to the systemic blood circulation. 13 Therefore, in order to realize clinical applications of IL-12-based cancer therapy, we need to explore innovative approaches that can elicit more effective tumor immunity at IL-12 doses lower than the maximum tolerance dosage.
On the basis of the relative benefits and risks of IL-12 for cancer treatment, we hypothesized that if small amounts of IL-12 can efficiently and persistently act on a large number of immune cells only within the local tumor tissue, such IL-12-based cancer immunotherapy may suppress adverse effects while maintaining excellent tumor immunity inducibility. However, it is known that infiltration of immune cells is generally hard to achieve in tumor tissue, and that several tumor models, such as Meth-A and MCH-1A1 tumors, are resistant to treatment with systemically administered IL-12 specifically due to poor tumor infiltration of lymphocytes. 14, 15 In addition, because conventional cancer immunotherapy research, involving the development of various vaccine strategies, has mainly focused on efficient induction and activation of the host's immune response to tumors, the methodology that can adequately recruit immune cells into tumor tissue is not yet established. In order to better control trafficking and biodistribution of immune cells in cancer immunotherapy, we and several other groups recently proposed novel strategies based on the application of chemokine-chemokine receptor coupling. [16] [17] [18] [19] [20] [21] [22] [23] Chemokines, which are small (8-14 kDa), basic, secreted proteins, regulate leukocytic migration and infiltration of local sites through cooperation with various cell adhesion molecules. 24 To date, more than 50 chemokines have been identified, and they compose a superfamily that contains four subgroups: C-chemokine, CC-chemokine, CXC-chemokine and CX3C-chemokine. 25 Within this superfamily, immune chemokines, which primarily target lymphocytes and DCs, would be useful molecules to improve the efficacy of cancer immunotherapy by augmenting tumor-infiltrating immune cells. We previously reported that tumorigenicity of the murine ovarian carcinoma cell line, OV-HM cells, was attenuated through enhanced tumor-infiltration by immune cells including NK and T cells, effected via in vitro transfection with CC-chemokine ligand-27 (CCL27) using RGD-fiber mutant adenoviral vector (AdRGD). 21 Although 70% of mice inoculated with CCL27-transfected OV-HM cells achieved complete rejection, these mice exhibited only limited long-term immunity in OV-HM-rechallenged experiments. Our results suggested that the tumorinfiltrating immune cells attracted by CCL27 gene transduction should be activated in a tumor-specific manner in order to induce more effective tumor immunity. In addition, because the ex vivo approach is not applicable for clinical use in patients with established malignant disease, we need to analyze both antitumor efficacy and activation state of tumor-infiltrating immune cells on direct in vivo transduction models using AdRGD-CCL27 plus other immunomodulators. Hence, a combinational therapy using IL-12-and CCL27-expressing vectors at low doses, for example, could potentially provide enhanced antitumor activity and long-term immune responses through the effective recruitment and activation of tumor-infiltrating immune cells, without the serious adverse effects of IL-12 leakage into the systemic circulation.
Thus, in the present study using the established murine OV-HM tumor (responsive to IL-12) and Meth-A tumor (unresponsive to IL-12) models, we compared intratumoral injections with AdRGD-IL12 alone, AdRGD-CCL27 alone, and the combination of AdRGD-IL12 and AdRGD-CCL27, in terms of tumor suppressive effects, frequency and activation state of tumor-infiltrating immune cells, as well as systemic adverse effects.
Results
Synergistic antitumor effects and long-term specific immune response induced by the combinational intratumoral injection of AdRGD-IL12 and AdRGD-CCL27
In order to evaluate the antitumoral effects of direct in vivo gene transduction in established OV-HM and Meth-A tumors, we investigated the changes in tumor size and the survival ratios of mice tested after intratumoral injection with various combinations of AdRGDs. We utilized a total vector dosage of 2 Â 10 7 PFU (plaque-forming unit) in the therapeutic experiments based on our observations that any group, including mice injected intratumorally with AdRGD-IL12 alone, did not show severe adverse effects, such as body weight reduction and sudden death, at dosages lower than this level (data not shown).
As shown in Figure 1a , OV-HM tumors injected with luciferase-expressing AdRGD (AdRGD-Luc; control vector) showed delayed growth compared with that of vehicle-injected tumors, and the growth of OV-HM tumors injected with AdRGD-CCL27 alone was nearly equal to that of AdRGD-Luc-injected tumors. These results suggested that OV-HM tumors were easily injured by direct in vivo transduction with AdRGDs, and that their growth was not affected by only CCL27 gene transduction, at least in this therapeutic model. On the other hand, intratumoral injection of AdRGD-IL12 alone induced obvious suppressive effects on OV-HM tumor growth, and even achieved complete regression in 4 of 7 mice (Figure 1b) . Although the survival ratio in mice treated with AdRGD-IL12 alone improved with increased vector dosage, there were also higher numbers of mice exhibiting body weight reduction (data not shown). Therefore, we examined whether the combination of AdRGD-IL12 and AdRGD-CCL27 could induce any synergistic effects for inhibition of OV-HM tumor growth without any concomitant side effects. Intratumoral co-injection of AdRGD-IL12 and AdRGD-CCL27 in a total vector dose ratio of 1:1 showed better antitumor effects than injection with AdRGD-IL12 alone, whereas treatment with AdRGD-IL12 and AdRGD-CCL27 in a ratio of 1:9 was ineffective compared with injection with AdRGD-CCL27 alone. Importantly, all mice treated with co-injection of AdRGD-IL12 and AdRGD-CCL27 in a vector dose ratio of 9:1 achieved complete regression of the primary tumor and survived more than 3 months after treatment without any severe adverse effects, such as body weight reduction and sudden death. In the established Meth-A tumor model, intratumoral injection of AdRGD-Luc alone or AdRGD-CCL27 alone did not affect tumor growth and survival ratio as compared with phosphate-buffered saline (PBS)-administration ( Figure  1c and d) . Although Meth-A tumors injected with AdRGD-IL12 alone showed marked regression, the combination of AdRGD-IL12 and AdRGD-CCL27 in a vector ratio of 9:1 produced very strong antitumor effects, similar to those seen in the OV-HM tumor model. Furthermore, most of the mice which achieved complete regression of primary tumors by the combination of AdRGD-IL12 and AdRGD-CCL27 in a ratio of 9:1 were also protected against rechallenge with the same tumor at 3 or 6 months after treatment (Table 1) . In contrast, rechallenge of different tumor (B16BL6 or CT26) of which haplotype matched to recipient induced palpable tumor formation in all primary tumor-regressed mice within 2 weeks, indicating that the systemic long-term immunity generated in mice receiving the AdRGD-IL12 and AdRGD-CCL27 combinational therapy was specific for primary tumors (OV-HM or Meth-A).
Taken together, these results clearly revealed that the combination of low doses AdRGD-CCL27 could synergistically enhance the efficacy of IL-12 gene therapy for Combinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al OV-HM and Meth-A tumors, and that the antitumor responses were both specific and long lasting.
Subset of immune cells responsible for antitumor efficacy of the combination of AdRGD-IL12 and AdRGD-CCL27
Next, in order to elucidate whether T-cell functions were involved in the induction of the observed antitumor effects, we carried out therapeutic protocols with intratumoral co-injection of AdRGD-IL12 and AdRGD-CCL27 in a ratio of 9:1 totaling 2 Â 10 7 PFU against established OV-HM and Meth-A tumors in BALB/c nude mice (data not shown). The AdRGD-IL12 and AdRGD-CCL27 combinational treatment was not able to restrain growth of OV-HM tumors established in nude mice. Although growth of Meth-A tumors was slightly delayed in nude mice treated with the AdRGD-IL12 and AdRGD-CCL27 combination, there were no individuals demonstrating tumor regression, unlike the experiments with immunocompetent mice. These results confirmed that tumor regression by the intratumoral co-injection with AdRGD-IL12 and AdRGD-CCL27 was mainly based on a T-cell-dependent immune response.
In addition, we performed in vivo depletion analysis using specific antibodies against CD4, CD8 and asialoGM1 in the OV-HM and Meth-A tumor model. As shown in Figure 2a , anti-OV-HM tumor effects of the combination of AdRGD-IL12 and AdRGD-CCL27 were attenuated by depletion of CD8 + T cells, CD4 + T cells and NK cells in B6C3F1 mice, with CD8-depletion being the most effective at abrogating the therapeutic effects. Moreover, OV-HM tumors in mice with depletion of both CD4 + and CD8 + T cells, in spite of treatment with AdRGD-IL12 and AdRGD-CCL27, showed more enhanced growth than those in mice with PBS-administration. On the other hand, growth suppressive effects of AdRGD-IL12 and AdRGD-CCL27 combinational therapy against Meth-A tumors were not affected by CD4 + T cell depletion, whereas the depletion of CD8 + T cells, NK cells and both CD4 + and CD8 + T cells attenuated antitumor effects, similar to the pattern shown in OV-HM tumor model (Figure 2b ). Therefore, we concluded that CD8 + CTLs, which were activated by the helper function of CD4 + T cells, were the predominant effector . In addition, reverse transcription-polymerase chain reaction (RT-PCR) analysis using isolated total RNA from OV-HM tumors subjected to the various treatments, showed that PCR products derived from transcripts of IFN-g, which are the secreted cytokines from IL-12-activated cells including Th1 cells and CTLs, were detected at high levels only in tumors injected with AdRGD-IL12 alone or AdRGD-IL12 plus AdRGD-CCL27 (Figure 5c ). Furthermore, CD4 + or CD8 + T cells isolated from Meth-A tumors with the co-injection of AdRGD-IL12 and AdRGD-CCL27 contained more IFN-g-producing cells than those Combinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al from tumors with other treatments in flow cytometric analysis (Figure 5d ). These findings support the observation that tumors co-injected with AdRGD-IL12 and AdRGD-CCL27 could recruit activated T cells in higher frequency compared with tumors treated with AdRGD-IL12 alone or AdRGD-CCL27 alone. Taken together, these data from immunohistochemical, RT-PCR and flow cytometric analyses demonstrate that the simultaneous production of IL-12 and CCL27 in tumor tissues could work synergistically, via the chemoattractant activity of CCL27 and the immunostimulating ability of IL-12, to expand the numbers of infiltrating T cells in an effector phase. Also, the frequencies of both perforin-positive cells and IFN-g-producing T cells in tumor parenchyma correlated closely with differences in the antitumor effects (Figures 1 and 5) , strongly suggesting that efficient accumulation of activated tumorspecific CTLs at a local tumor site is a key factor for establishment of efficacious cancer immunotherapy.
Reduction of adverse effects caused by IL-12 in the combinational therapy using AdRGD-IL12 and AdRGD-CCL27
In our therapeutic experiments, severe adverse effects including body weight reduction and sudden death were not observed in any treated mice. However, mice achieving complete regression of primary Meth-A tumor by treatment with AdRGD-IL12 alone showed some histopathological changes in the lung, liver and spleen. In all lungs collected from mice treated with AdRGD-IL12 alone, rare to moderate levels of lymphocyte infiltration into the perivascular lymph sinus were observed (Figure 6a and g ), and hemorrhagic lesions were also often found. Also, microgranuloma, interstitial lymphocyte infiltration and extramedullary hematopoi- Figure 3 Images of infiltrating T cells in OV-HM tumors injected with the IL-12/CCL27 combination. OV-HM cells were intradermally inoculated into the flanks of B6C3F1 mice at 10 6 cells/mouse. The tumors (7-9 mm in diameter) were injected with AdRGD-Luc alone (a, c, e and g) or AdRGD-IL12 plus AdRGD-CCL27 in a ratio of 9:1 (b, d, f and h) at the same dose totaling 2 Â 10 7 PFU. On day 6 after the intratumoral injections, immunohistochemical staining against CD3 (a and b), CD4 (c and d), CD8 (e and f) and perforin (g and h) was performed using frozen tumor sections. Original magnifications are Â 400.
Combinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al esis were rarely observed in the livers from 4 of 6 mice (Figure 6b and g ), and four of six specimens of spleen exhibited augmentation of extramedullary hematopoiesis (Figure 6c and g ). On the other hand, in the group treated with the AdRGD-IL12 and AdRGD-CCL27 combination, the extramedullary hematopoiesis in the liver was not observed, whereas lymphocyte infiltration and lung hemorrhages were less evident compared with the group treated with AdRGD-IL12 alone (Figure 6d, e  and g ). In addition, the enhancement of extramedullary hematopoiesis was not observed in splenic examinations of mice treated with the AdRGD-IL12 and AdRGD-CCL27 combination (Figure 6f and g ). These results indicate that IL-12 disseminated from local tumor sites into the systemic circulation might cause undesired histopathological changes in mice treated with AdRGD-IL12 alone, and that the combination of AdRGD-CCL27 at low doses was a promising approach for suppressing the adverse effects in IL-12 gene therapy for cancer.
Discussion
The development of cancer immunotherapy aims for sufficient induction of the tumor-specific immune responses to a level capable of tumor rejection and regression, and involves three criteria for the immunological elimination of established tumor mass: (i) sufficient numbers of immune cells capable of recognizing tumor-associated antigens (TAAs) must be generated in vivo; (ii) these cells must distribute to local tumor tissue and infiltrate into the tumor parenchyma; and (iii) were intradermally inoculated into the flanks of syngeneic mice at 10 6 or 2 Â 10 6 cells/mouse, respectively. The tumors (7-9 mm in diameter) were injected with AdRGD-Luc alone, AdRGD-IL12 alone, AdRGD-CCL27 alone, or the AdRGD-IL12 and AdRGD-CCL27 combination in a ratio of 9:1 at the same dose totaling 2 Â 10 7 PFU. PBS was injected into the tumors as a control. On day 6 after the intratumoral injections, immunohistochemical staining against CD3, CD4 and CD8 was performed using frozen tumor sections. These immunohistochemical sections were used to assess the numbers of CD3 + (a and b), CD4 + (c and d) and CD8 + (e and f) cells infiltrating into tumor parenchyma by counting six fields per specimen under Â 400-magnification. The data represent the mean7s.d. of results from three tumors. Statistical analysis was carried out using Welch's t-test: *Po0.05, **Po0.01.
Combinational cancer immunogene therapy using IL-12 and CCL27
J-Q As chemokines regulate leukocytic migration and infiltration of local sites, they are now considered important molecules for augmenting tumor-infiltrating immune cells in cancer immunotherapy. In fact, recent studies in several murine tumor models have provided experimental evidence that introduction of chemokines into the tumor environment results in the recruitment of relevant leukocyte subsets and decreases tumorigenicity of malignant cells. [16] [17] [18] [19] [20] [21] [22] [23] However, most of these studies used ex vivo gene transfection methods that are not suitable for use within clinical settings, especially for the treatment of patients with established malignancies, and few reports have showed that direct in vivo transduction with chemokine genes alone could induce complete Combinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al regression of pre-existing tumor mass. Our previous work also demonstrated that whereas intratumoral injections of AdRGD carrying one chemokine, CCL19, could attract massive numbers of T lymphocytes in established murine B16BL6 melanomas, the antitumor efficacy of this treatment was very modest, resulting in only a slight delay of tumor growth. 23 These results strongly suggested that the augmentation of tumorinfiltrating immune cells due to chemokine gene transduction in itself is insufficient, and that subsequent activation of the recruited immune cells by another treatment is required for the induction of excellent antitumor response. On the other hand, in a number of animal models, multifunctional cytokines, such as IL-2 and IL-12, demonstrate strong antitumor activity by promoting the proliferation and activation of T and NK cells, and by overcoming some immunosuppressive factors in tumor tissues. Although the utility of recombinant protein therapy or gene therapy using these immunomodulators has been widely inspected in clinical trials, a major drawback involves serious adverse effects caused by high systemic peak concentrations associated with large or frequent doses. 11, 12 Therefore, establishing a combinational approach, which can maximize the benefits of both chemokines and immunostimulating cytokines, is necessary when designing optimal immunotherapy for malignancies. Dilloo et al. 33 reported that in vitro cotransfection with the chemokine XCL1 and the cytokine IL-2 into A20 tumor cells using retrovirus vectors greatly expanded tumor-infiltrating T cells attracted by XCL1 and protected against the growth of established tumors in a CD4 + and CD8 + T-cell-dependent manner. Also, Emtage et al. 34 demonstrated that intratumoral injection with double-recombinant adenoviral vectors expressing XCL1 along with either IL-2 or IL-12 could elicit potent and long-lasting antitumor responses. These approaches, termed 'attraction-expansion', are based on the assumption that if more immune cells could be recruited to the tumor site by chemokines and subsequently activated by cytokines, the antitumoral immune response could then be significantly enhanced.
In the present study, we selected as a co-stimulator, a chemokine CCL27 -which in our ex vivo transfection model 21 could attenuate tumorigenicity of murine OV-HM ovarian carcinoma cells by augmenting tumorinfiltrating T and NK cells -for promoting the antitumor efficacy and improving the safety of IL-12 gene therapy for established tumors. OV-HM tumors are relatively responsive to IL-12-based therapy; in contrast, systemic administration of IL-12 fails to inhibit Meth-A tumor growth because of a lack of immune cell migration and infiltration into tumor stroma. 14, 15 In the present therapeutic experiments using AdRGDs capable of efficient gene transduction in various tumors, the IL-12 and CCL27 combinational treatment demonstrated excellent antitumor effects against both established OV-HM and Meth-A tumors compared with treatment with either vector alone, and, more importantly, induced complete tumor regression in all tested OV-HM tumor-bearing mice and in 12 of 13 Meth-A tumor-bearing mice. Moreover, the antitumor responses elicited by the combinational therapy with AdRGD-IL12 and AdRGD-CCL27 were tumor-specific and long lasting as determined by rechallenge experiments and hence demonstrated a protective immunity. These data indicate that synergic effects arising from the IL-12/CCL27 combination may promote more efficacious and safer IL-12 gene therapy for cancer at doses lower than the maximum tolerance dosage. Figure 6 Histopathological examination of lung, liver and spleen in Meth-A tumor-bearing mice treated with the IL-12/CCL27 combination intratumoral injection. BALB/c mice were intradermally inoculated with 2 Â 10 6 Meth-A cells into the flanks. The tumors (7-9 mm in diameter) were injected with AdRGD-IL12 alone or the AdRGD-IL12 and AdRGD-CCL27 combination in a ratio of 9:1 at the same dose totaling 2 Â 10 7 PFU. Three months later, lung (a and d), liver (b and e) and spleen (c and f) were harvested from mice in which the primary tumors were judged to have completely regressed, and then HE staining was performed using paraffinembedded tissue sections. Original magnifications are Â 300. (g): Histopathological changes (lymphocyte infiltration in lung and extramedullary hematopoiesis in liver and spleen) were scored as: 0, no; 1, rare; 2, mild; 3, moderate; 4, severe. (J) AdRGD-IL12 alone; (K) AdRGD-IL12 plus AdRGD-CCL27. For extramedullary hematopoiesis in liver and spleen, significant differences (Po0.05) were observed between AdRGD-IL12 plus AdRGD-CCL27 group and AdRGD-IL12 alone group in Mann-Whitney U-test.
J-Q Gao et al Therefore, we also investigated the antitumoral mechanisms associated with the synergy of IL-12 and CCL27 by in vivo depletion assays and immunohistochemical analysis. The immune system is roughly classified into cellular immunity and humoral immunity, and an optimal immune response is achieved by the balanced activation of both systems. Cellular immune responses including the activation of NK cells and CTLs play a more important role in elimination of tumor cells by tumor immunity than humoral immune responses accompanied by antibody production from B cells. The antitumor effects in the IL-12/CCL27 combinational therapy were T-cell-dependent, with the effector activity of CD8 + CTLs, rather than with the NK activity, mainly contributing to the regression of the pre-existing tumors. This finding reasonably accounts for the generation of systemic long-term specific immunity in mice receiving the IL-12/CCL27 combinational therapy because T-celldependent immunity possesses both effector and memory phases. In addition, tumors injected with the IL-12/ CCL27 combination showed more enhanced accumulation of CD3 + T cells than those injected with AdRGD-IL12 alone, whereas treatment with AdRGD-CCL27 alone was the most effective. This result demonstrates that CCL27 is a strong recruiter for T cells into tumor tissue, and is consistent with our previous data in an ex vivo transfection model. 21 In T-cell subset analysis, the IL-12/CCL27-treated group induced the infiltration of CD8 + CTLs -the major effector cells in the in vivo depletion assays -into tumor parenchyma more efficiently than the group treated with AdRGD-CCL27 alone even though the total vector dosage of AdRGD-CCL27 in the former was only one-tenth of that in the latter. Moreover, the infiltrating immune cells in tumors treated with AdRGD-IL12 alone or IL-12/CCL27 together were highly activated, as determined by the number of perforin-positive cells and IFN-g-producing T cells in tumor tissue. On the other hand, most of the immune cells recruited by injection with AdRGD-CCL27 alone were in an inactivated or naive state, explaining why treatment with AdRGD-CCL27 alone did not show significant antitumor effects in spite of its ability to augment T-cell-infiltration. IL-12 can activate signal transducer and activator of transcription (STAT)4 via binding to its receptor, and STAT4 plays an important role within the microenvironment for Th1-biased immune responses, by expressing a set of genes such as IFN-g and IL-18 receptor a subunit. 35 In addition, the cellular immune response including effector activity of CTLs and NK cells is dominantly activated by the helper function of Th1 cells. 36 On the basis of our current results, we determined that the synergic antitumor responses in the IL-12/CCL27 combinational therapy reflected both the CCL27-induced augmentation of tumor-infiltrating immune cells and the subsequent IL-12-stimulated enhancement of effector activity.
In our experimental models, mice achieving complete regression of the primary tumors because of AdRGD-IL12 treatment alone showed some histopathological changes within lung, liver and spleen, for example lymphocyte infiltration and extramedullary hematopoiesis. Although the mechanisms associated with these peripheral adverse effects remain unclear, we speculate that IL-12 spreading into the systemic blood circulation from tumor tissues potentiated peripheral hematopoiesis because the administration of recombinant IL-12 results in significant splenic hyperplasia with increased progenitor cells, increased circulating progenitor cells and bone marrow hypoplasia with decreased progenitor cells in a time-and dose-dependent manner. 37, 38 On the other hand, the IL-12/CCL27 combinational treatment could reduce the side effects observed after complete tumor regression, suggesting that most of the IL-12 produced in tumor tissues might have been utilized for local activation of tumor-infiltrating immune cells; this improved therapeutic safety was probably related to the consumption of intratumoral IL-12 by recruited immune cells.
In conclusion, our results revealed that cotransduction with IL-12 and CCL27 genes into established tumors by using AdRGD could promote antitumor responses through both the recruitment and activation of tumorinfiltrating immune cells, and would greatly contribute to the development of an efficacious and safe cancer immunogene therapy. At present, in order to expand our combinational cancer immunogene therapy to metastatic tumors, in which intratumoral injection of vectors is physically difficult, we are pushing forward with the development of vectors, which can be transductionally and transcriptionally targeted to tumors and also with methods to specifically deliver therapeutic genes into tumor cells by systemic administration. ), a melanoma cell line originating from C57BL/6 mice, were distributed from the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). HEK293 cells and B16BL6 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. Female (C57BL/6 Â C3H/He) F1 (B6C3F1) mice, BALB/c mice and BALB/c nude mice were purchased from Japan SLC Inc. (Hamamatsu, Japan), and were used at 6-8 weeks of age. Animal experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
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Materials and methods
Cell lines and mice
Vectors
Because most malignant tumors express little coxsackieadenovirus receptor, which is the primary receptor for conventional adenoviral vectors, we utilized AdRGDs, which are infectivity-enhanced adenoviral vectors with an RGD-4C motif in the adenoviral fiber-knob region. Replication-deficient AdRGD was based on the adenovirus serotype 5 backbone with deletions of E1 and E3 regions. The RGD-4C sequence for av-integrin-targeting was inserted into the HI loop of the fiber knob using a two-step method, as previously described. 42 AdRGDCombinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al IL12, 13 AdRGD-CCL27, 21 and AdRGD-Luc 42 under the control of the cytomegalovirus promoter were previously constructed by an improved in vitro ligation method. [42] [43] [44] All recombinant AdRGDs were propagated in HEK293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at À801C. Titers of infective AdRGD particles (PFU) were evaluated by the end-point dilution method using HEK293 cells.
Tumor inoculation and intratumoral administration of vectors in animal experiments
B6C3F1 mice, BALB/c mice or BALB/c nude mice were intradermally inoculated with 10 6 OV-HM cells or 2 Â 10 6
Meth-A cells into the flank. After established tumor diameters reached 7-9 mm, AdRGD-IL12 alone, AdRGD-CCL27 alone or AdRGD-IL12 plus AdRGD-CCL27 in a ratio of 1:9, 1:1 or 9:1 were intratumorally injected at a total of 2 Â 10 7 PFU in 50 ml PBS. AdRGD-Luc was used as a control vector. Tumor growth was monitored twice or three times a week by measurement of the major axis of the tumors using microcalipers. The data were expressed as a relative tumor size to the initial tumor size. The mice were euthanized when the tumor measurements were greater than 20 mm. On day 90 after treatment, mice without palpable tumor masses were judged to be individuals that could potentially achieve complete regression.
Tumor rechallenge experiments in mice achieving complete regression of primary tumors Three or six months after treatment with the combination of AdRGD-IL12 and AdRGD-CCL27 in a 9:1 ratio totaling 2 Â 10 7 PFU, mice that achieved complete regression of primary tumors were rechallenged with 10 6 OV-HM cells, 3 Â 10 5 B16BL6 cells, 10 6 Meth-A cells or 3 Â 10 5 CT26 cells by intradermal injection into the opposite flank of the first tumor inoculation. On day 60 after tumor rechallenge, the tumor-free mice were judged to be individuals that had achieved complete tumor rejection.
In vivo depletion analysis
Ascites from BALB/c nude mice intraperitoneally injected with GK1.5 hybridoma (anti-CD4) 45 or 53-6.72 hybridoma (anti-CD8) 46 were kindly provided by Professor Hiroshi Yamamoto (Department of Immunology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan). Mice bearing OV-HM or Meth-A tumor were intratumorally injected with the combination of AdRGD-IL12 and AdRGD-CCL27 in a ratio of 9:1 totaling 2 Â 10 7 PFU on day 0, and intraperitoneally injected seven times on days À3, À2, À1, 0, 5, 10 and 15 with 100-ml GK1.5 or 53-6.72 ascites, or 40-ml rabbit anti-asialoGM1 antiserum (Wako Pure Chemical Industries, Ltd, Osaka, Japan). The depletion of T-cell subsets and NK cells was confirmed by flow cytometric analysis of peripheral blood and splenic cells. Tumor growth was monitored as described above. The mice were euthanized when the tumor measurements were greater than 20 mm.
Immunohistochemical examination of tumor sections
Tumor-bearing mice were killed 6 days after the intratumoral injection of AdRGD. For immunohistochemical analysis, the fresh tumor nodules were embedded in OCT compound (Sakura Finetechnical Co., Ltd, Tokyo, Japan), and frozen in liquid nitrogen. Frozen sections (6 mm in thickness) were fixed in 4% paraformaldehyde, washed with PBS and then stored at À801C until needed for subsequent procedures. The immunostaining procedures, which included blocking for endogenous peroxidase activity with peroxidase blocking solution (Dako Japan Co., Ltd, Kyoto, Japan), blocking for nonspecific binding of the subsequently used immunoreagents with 5% bovine serum albumin, incubation with optimal dilution of antibody, incubation of reagent(s) for detection, and development with 3,3 0 -diaminobenzidine, were carried out on an automated immunostaining system (Autostainer Plus, Dako Japan). Between all incubation steps, the tumor sections were washed with Tris-buffered saline containing Tween-20. The following were used as primary antibodies: rabbit anti-human CD3 polyclonal antibody (Dako Japan), rat anti-mouse CD4 monoclonal antibody (mAb) (RM4-5; BD Biosciences, San Jose, CA, USA), rat anti-mouse CD8 mAb (KT15; Serotec Co., Ltd, Sapporo, Japan) and rat anti-mouse perforin mAb (CB5.4; Abcam, Paris, France). Rabbit anti-human CD3 polyclonal antibody was detected with ENVISION+ Rabbit/HRP (Dako Japan). Other primary antibodies were detected with HRPconjugated anti-rat Ig (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and CSA II System (Dako Japan). The sections were finally counterstained with hematoxylin. The numbers of immunostained cells in six fields per specimen were counted under a light microscope using Â 400-magnification.
RT-PCR analysis for IFN-g expression levels in tumor tissues
OV-HM tumors were collected 6 days after intratumoral injection of AdRGD, and total RNA was isolated using TRI Reagent (SIGMA-ALDRICH Japan, Tokyo, Japan) according to the manufacturer's instructions. RT proceeded for 60 min at 501C in a 20 ml reaction mixture containing 2 mg total RNA treated with DNase I, 4 ml 5 Â RT buffer, 0.1 M dithiothreitol, 0.1 mM dNTP mix, 0.5 mg oligo (dT) 20 , 1 ml RNase inhibitor and 1 ml SuperScript III (Invitrogen, Carlsbad, CA, USA). PCR amplification of IFN-g and b-actin transcripts was performed in a 50 ml reaction mixture containing 2 ml of RT-material, 5 ml 10 Â PCR buffer, 0.25 ml Ampli Taq DNA polymerase (TOYOBO Co., Ltd, Osaka Japan), 1 ml dimetylsulfoxide, 0.2 mM dNTP and 0.4 mM primers. The sequences of the specific primers were as follows; murine IFN-g: forward, 5 0 -gct ttg cag ctc ttc ctc at-3 0 ; reverse, 5 0 -tga gct cat tga atg ctt gg-3 0 ; murine b-actin: forward, 5 0 -tgt gat ggt ggg aat ggg tca g-3 0 ; reverse, 5 0 -ttt gat gtc acg cac gat ttc c-3 0 . After denaturation for 4 min at 961C, 3 sequential steps, denaturation for 30 s at 961C, annealing for 30 s at 601C and extension for 30 s at 721C, were repeated for 30 cycles, ending with a final extension step for 4 min at 721C. The PCR products was electrophoresed through a 1.5% agarose gel, stained with ethidium bromide and visualized under ultraviolet radiation. The expected PCR product sizes were 379 bp (IFN-g) and 514 bp (b-actin).
Flow cytometric analysis for tumor-infiltrating T cells
Meth-A tumors were dissected 6 days after intratumoral injection of AdRGD, and then chopped into small pieces Combinational cancer immunogene therapy using IL-12 and CCL27 J-Q Gao et al using a razor blade before incubation with a mixture of collagenase (1 mg/ml, Wako Pure Chemical Industries, Ltd) dissolved in Hanks' balanced salt solution for 60 min at 371C. The cells were passed through a 70-mm nylon strainer to remove any debris, recovered by centrifugation and resuspended in complete medium. Then, the cell suspension was overlaid on 40 and 80% Percoll gradient and centrifuged at 2000 r.p.m. for 20 min at room temperature. After centrifugation, cells deposited at the interface were harvested and washed two times with complete medium. Phenotype of T cells isolated from tumors treated with various AdRGD was confirmed by flow cytometric analysis. Briefly, 10 6 cells were incubated on ice for 20 min with 100 ml of staining buffer (PBS containing 2% FBS and 0.09% NaN 3 ) containing anti-FcgRII/III mAb (93, rat IgG 2a,l ; eBioscience, San Diego, CA, USA) to block nonspecific binding of the subsequently used mAbs, and then the cells were stained with FITC-conjugated anti-mouse CD4 mAb (GK1.5, rat IgG 2b,k ; eBioscience) or FITC-conjugated anti-mouse CD8 mAb (53-6.7, rat IgG 2a,k ; eBioscience). After incubation for 20 min, cells were washed with staining buffer, fixed with Cytofix/Cytoperm Buffer (BD Biosciences) for 15 min and permeabilized with Perm/ Wash Buffer (BD Biosciences). Intracellular IFN-g was stained with PE-conjugated anti-mouse IFN-g mAb (XMG1.2, rat IgG 1,k ; BD Biosciences). After incubation for 20 min, the stained cells were analyzed for CD4/CD8 and IFN-g expression by a FACSCalibur flow cytometer using CellQuest software (BD Biosciences).
Histopathological examination of tissue sections
Tumor-regressed mice were killed 3 months after the intratumoral injection with AdRGD-IL12 alone or the combination of AdRGD-IL12 and AdRGD-CCL27 in a ratio of 9:1 totaling 2 Â 10 7 PFU. The lungs, liver and spleen were harvested from each of these mice, placed in neutral 10% formalin/PBS and embedded in paraffin. Sections (5 mm) were prepared for hematoxylin and eosin (HE) staining, and then histopathological examination was performed at Applied Medical Research Laboratory (Osaka, Japan).
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